Hip kinetics during gait are clinically meaningful outcomes in young boys with Duchenne muscular dystrophy.

[1]  H. Hillege,et al.  European Medicines Agency review of ataluren for the treatment of ambulant patients aged 5 years and older with Duchenne muscular dystrophy resulting from a nonsense mutation in the dystrophin gene , 2015, Neuromuscular Disorders.

[2]  A. Mayhew,et al.  Measuring clinical effectiveness of medicinal products for the treatment of Duchenne muscular dystrophy , 2015, Neuromuscular Disorders.

[3]  T. Partridge,et al.  What Can We Learn From Clinical Trials of Exon Skipping for DMD? , 2014, Molecular therapy. Nucleic acids.

[4]  E. Hoffman,et al.  Pharmacologic management of Duchenne muscular dystrophy: target identification and preclinical trials. , 2014, ILAR journal.

[5]  Jay J. Han,et al.  The cooperative international neuromuscular research group Duchenne natural history study: Glucocorticoid treatment preserves clinically meaningful functional milestones and reduces rate of disease progression as measured by manual muscle testing and other commonly used clinical trial outcome measur , 2013, Muscle & nerve.

[6]  S. Pandya,et al.  Review of Phase II and Phase III clinical trials for Duchenne muscular dystrophy , 2013 .

[7]  Francesco Muntoni,et al.  Development of a functional assessment scale for ambulatory boys with Duchenne muscular dystrophy. , 2012, Physiotherapy research international : the journal for researchers and clinicians in physical therapy.

[8]  E. Pavan,et al.  Early signs of gait deviation in Duchenne muscular dystrophy. , 2011, European journal of physical and rehabilitation medicine.

[9]  S. Gasperini,et al.  Functional changes in Duchenne muscular dystrophy , 2011, Neurology.

[10]  E. Hoffman,et al.  Restoring dystrophin expression in duchenne muscular dystrophy muscle progress in exon skipping and stop codon read through. , 2011, The American journal of pathology.

[11]  S. Õunpuu,et al.  Efficacy of clinical gait analysis: A systematic review. , 2011, Gait & posture.

[12]  K. Wagner.  Approaching a new age in Duchenne muscular dystrophy treatment , 2008, Neurotherapeutics.

[13]  F. Muntoni,et al.  The status of exon skipping as a therapeutic approach to duchenne muscular dystrophy. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[14]  Jay J. Han,et al.  The 6‐minute walk test in Duchenne/Becker muscular dystrophy: Longitudinal observations , 2010, Muscle & nerve.

[15]  C. Schmoor,et al.  Treatment of Duchenne muscular dystrophy with ciclosporin A: a randomised, double-blind, placebo-controlled multicentre trial , 2010, The Lancet Neurology.

[16]  S. Nadeau,et al.  Gait patterns comparison of children with Duchenne muscular dystrophy to those of control subjects considering the effect of gait velocity. , 2010, Gait & posture.

[17]  A. Nicorici,et al.  Classification of the Gait Patterns of Boys With Duchenne Muscular Dystrophy and Their Relationship to Function , 2010, Journal of child neurology.

[18]  Jay J. Han,et al.  The 6‐minute walk test as a new outcome measure in Duchenne muscular dystrophy , 2010, Muscle & nerve.

[19]  R. Finkel,et al.  Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management , 2010, The Lancet Neurology.

[20]  Anna Carla Turconi,et al.  Gait pattern in Duchenne muscular dystrophy. , 2009, Gait & posture.

[21]  C. Angelini.  The role of corticosteroids in muscular dystrophy: A critical appraisal , 2007, Muscle & nerve.

[22]  Victoria L Chester,et al.  A comparison of kinetic gait parameters for 3-13 year olds. , 2006, Clinical biomechanics.

[23]  D. Matthews,et al.  Corticosteroid Treatment and Functional Improvement in Duchenne Muscular Dystrophy: Long-Term Effect , 2005, American journal of physical medicine & rehabilitation.

[24]  J. Fock,et al.  Functional ability and muscle force in healthy children and ambulant Duchenne muscular dystrophy patients. , 2005, European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society.

[25]  Eric Watelain,et al.  A comparison of gait in spinal muscular atrophy, type II and Duchenne muscular dystrophy. , 2004, Gait & posture.

[26]  R. Abresch,et al.  Profiles of neuromuscular diseases. Becker's muscular dystrophy. , 1995, American journal of physical medicine & rehabilitation.

[27]  R. Abresch,et al.  Becker's muscular dystrophy , 1995 .

[28]  J. Hsu,et al.  Gait and Posture Changes in the Duchenne Muscular Dystrophy Child , 1993, Clinical orthopaedics and related research.

[29]  J. Miller,et al.  Randomized, double-blind six-month trial of prednisone in Duchenne's muscular dystrophy. , 1989, The New England journal of medicine.

[30]  R. Olshen,et al.  The Pathomechanics of Gait in Duchenne Muscular Dystrophy , 1981, Developmental medicine and child neurology.